Sinopharm Group Co (HK:1099) has released an update.
Sinopharm Group Co.’s subsidiary, China National Medical Device Co., Ltd., reported a 6.94% decrease in revenue and a significant 36.33% drop in operating profit for the first nine months of 2024 compared to the previous year. Additionally, the total comprehensive income attributable to the parent company owners fell by 40.08%, while the net cash flow from operating activities saw an increase in deficit by 20.61%. Despite these challenges, the company’s total assets grew by 9.91% during the same period.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.
